Comparing JnC 7 and JnC 8
JNC 8 does not attempt to redefine the basic concepts of hypertension or prehypertension which were defined in JNC 7. The panel believes that the 140/90 mm Hg definition from JNC 7 remains reasonable. However, the new guidelines focus on establishing new thresholds for initiating pharmacologic treatment and new blood pressure goals for certain subpopulations. Whereas the JNC 7 specified separate treatment goals for "uncomplicated" hypertension and for subsets with various comorbid conditions, the JNC 8 gives similar treatment goals for all hypertensive populations except when the review of evidence supports different goals for a particular subpopulation. Within the general population, the JNC 8 distinguishes between different blood pressure goals for those 60 years or older and those under 60 years. In addition, specific goals of treatment are specified for patients with chronic kidney disease (CKD) and with diabetes mellitus (DM).
The recommended drug therapy in the JNC 8 guideline differs from the previous guideline. JNC 7 recommended five classes to be considered as initial therapy but recommended thiazide-type diuretics as initial therapy for most patients without a compelling indication for another class. JNC 8, on the other hand, recommends four specific medication classes to be used as initial therapy. These four classes include angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs), calcium channel blockers, and thiazide diuretics. Within JNC 8, there are also specific medication classes recommended based on evidence review with regard to race (black versus nonblack), CKD, and DM. This is in contrast to JNC 7 which not only specified particular medication classes for those with DM and CKD but also made specific recommendations based on the presence of other compelling indications, such as heart failure, myocardial infarction, stroke, and high cardiovascular disease risk.
Three QuesTions used in FormulaTion oF The guideline
The JNC 8 makes nine recommendations. The following three questions were used by panel members to guide the formulation of eight of the nine recommendations:
pertensive pharmacologic therapy at specific blood pressure thresholds improve health outcomes? (Recommendations 1-5) 2. In adults with hypertension, does treatment with antihypertensive pharmacologic therapy to a specified blood pressure goal lead to improved health outcomes? (Recommendations 1-5) 3. In adults with hypertension, do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcomes? (Recommendations 6-8)
The reCommendaTions
Recommendations 1 through 5 specify blood pressure thresholds for initiating pharmacologic treatment and also blood pressure goals once treatment is initiated. 
Recommendation 9
This recommendation stresses the importance of attaining and maintaining the goal blood pressure. If the goal is not attained in one month, JNC 8 recommends adjusting the medication regimen by either increasing the initial drug dose or adding a second drug that is listed in Recommendation 6. If the blood pressure goal is not reached using two drugs, then it is recommended to add a third drug from the list. This recommendation also notes that an ACE-I and ARB should not be used together in the same patient.
If the blood pressure goal is not reached using the drugs from the classes noted in Recommendation 6 due to the need for more than three drugs or due to contraindication, then JNC 8 does allow the use of other antihypertensive drugs from other classes. Referral to a hypertension specialist may be indicated if the blood pressure goal is not achieved or for more complicated patients who may also need additional clinical consultation.
